Information below provided by the Pharmaceutical Company.

Adavosertib (AZD1775)

Agent Description

Adavosertib is a potent, selective inhibitor of WEE1 that deregulates CDK1 and CDK2 activity leading to abrogation of the replication stress response and the G2/M checkpoint.

Mechanism of Action

WEE1 kinase inhibition

Classification

Small molecule WEE1 kinase inhibitor

Molecular Targets

WEE1

Monograph

Adavosertib is under investigation as a monotherapy in cancers with high replication stress and in combination with chemotherapy and the PARP inhibitor olaparib.

Studies of Interest

Areas of interest:

• Monotherapy other than in ovarian, TNBC, SCLC, endometrial, prostate, renal, AML, sarcoma and CRC
• Combinations with olaparib other than in ovarian, endometrial, pancreas
• Combination with other DNA damage response (DDR) agents (e.g., ATR inhibitors, ATM inhibitors, other novel checkpoint kinase inhibitors)
• Combination with Immunotherapy
• Combination with Chemotherapy, including novel chemotherapy and formulations
• Combination with radiation
• Novel/Novel agent combinations (e.g., VEGF, mTOR, AKT)
• Other study designs:
  • Neo-adjuvant therapy
  • Window studies
  • Maintenance therapy
  • Agent administration sequencing studies
  • Basket-type approaches with DDR agents
  • Specific molecular segmented patient populations

Areas NOT of interest:

• Monotherapy in ovarian, TNBC, SCLC, endometrial, prostate, renal, AML, sarcoma and CRC
• Combinations with olaparib in ovarian, endometrial, pancreas
• Combinations with carboplatin, gemcitabine or PLD
• Studies in AML
• Combination with Radiation or Cisplatin in GBM
• Combinations in HNSCC
• Combinations with Durvalumab/Tremelimumab
• Pediatrics

Information collaborator would like included in investigator proposals

Clear line of site of how the study would lead to a registration intent study in the proposed setting